Marius Miglinas, M.D., Ph.D.

President, Lithuanian Kidney Foundation

President, Lithuanian Hypertension Society

Prof. Miglinas currently serves as a President of Lithuanian Kidney Foundation and as a President of Lithuanian Hypertension Society. He also takes a lead to Nephrology Center and Center for Rare Kidney Diseases at the Vilnius University hospital, Vilnius University in Vilnius (Lithuania).

Dr. Miglinas received his medical degree from Vilnius University in Lithuania. He trained as an intern in Vilnius, and as a Senior House Officer (International Society of Nephrology Fellow) at Glasgow University Western Infirmary in Scotland, U.K.

Dr. Miglinas received the award of Matsumae International Foundation (Japan) to study uremic toxicity in chronic renal failure patients at the Nagoya University, Nagoya (Japan) under guidance of prof. T.Niwa in 2002. In 2007 he has been trained as an EDTA/ERA Fellow in Vienna University Hospital (Austria) in the field of chronic kidney disease and kidney transplantation. Dr. Miglinas has also been trained at the Transplant and Renal Education Center, Westmead Hospital, Sydney University (Australia) under guidance of prof. J. Chapman in 2013.

Dr. Miglinas' research interests are renal biopsy and glomerular involvement in primary and secondary glomerular diseases, diabetic kidney disease, thrombotic microangiopathies, Fabry disease, rare tubulopathies, kidney involvement in arterial hypertension, management of hypertension in renal patients and diabetics, kidney and pancreas/pancreatic islets transplantation, interventional nephrology and chronic kidney disease epidemiology. His expertise includes glomerular, diabetic and rare kidney disease management, treatment of hypertension in chronic kidney disease and resistant hypertension work-up, dialysis-related complications and kidney transplant recipients‘ long-term management. He has published over 200 articles in the nephrology field.

Dr. Miglinas is frequently invited to speak throughout Lithuania, Baltic states and abroad.